348 related articles for article (PubMed ID: 28478356)
1. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label Study of Adjunctive Dextromethorphan/Quinidine in Treatment-Resistant Depression.
Wang PR; Yavi M; Lee H; Kotb Y; Shora L; Park LT; Zarate CA
J Clin Psychopharmacol; 2023 Sep-Oct 01; 43(5):422-427. PubMed ID: 37683231
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice.
Saavedra JS; Garrett PI; Honeycutt SC; Peterson AM; White JW; Hillhouse TM
Pharmacol Biochem Behav; 2020 Oct; 197():173003. PubMed ID: 32755625
[TBL] [Abstract][Full Text] [Related]
5. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
Lauterbach EC
Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
[TBL] [Abstract][Full Text] [Related]
6. Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
Lauterbach EC
Psychopharmacol Bull; 2016 Aug; 46(2):53-58. PubMed ID: 27738380
[TBL] [Abstract][Full Text] [Related]
7. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
[TBL] [Abstract][Full Text] [Related]
8. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
11. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
[TBL] [Abstract][Full Text] [Related]
13. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
[TBL] [Abstract][Full Text] [Related]
14. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Thisted RA; Klaff L; Schwartz SL; Wymer JP; Culligan NW; Gerard G; Pope LE; Berg JE
Clin Ther; 2006 Oct; 28(10):1607-18. PubMed ID: 17157116
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
16. Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence.
Parincu Z; Iosifescu DV
Expert Rev Neurother; 2023 Mar; 23(3):205-212. PubMed ID: 36943010
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).
Iosifescu DV; Jones A; O'Gorman C; Streicher C; Feliz S; Fava M; Tabuteau H
J Clin Psychiatry; 2022 May; 83(4):. PubMed ID: 35649167
[No Abstract] [Full Text] [Related]
18. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
